-
Not all funding is created equal – learn about non-dilutive $ sources and how you might get them at
#JLABSSD on Dec. 3rd. Register now https://bit.ly/2NDNgza -
#JLABSSD resident Entos announces a new partnership! Their Fusogenix drug delivery platform will be used to develop nex gen therapies for inflammatory & autoimmune diseases https://jlabs.buzz/arn -
Have you always wondered what it’s like to be part of the JLABS community? Get to know the
#JLABSSD family on 1/29
http://bit.ly/2N6WVgY pic.twitter.com/97EySawaQ4
-
Congratulations to Avidity Biosciences, a
#JLABSSD alumni, on their $35M research and licensing collaboration for their antibody-oligonucleotide technology! Under the new deal, they could receive additional funds of up to $405M in…https://lnkd.in/ecHt4Yp https://lnkd.in/e9aDyG4 -
In step with the rapid transformation of startup business models, seed financing continues to evolve. Join
#JLABSSD Head Sanjay Mistry today to learn more about key changes that can impact life science innovators in 2020.#BiotechShowcase#JPM20pic.twitter.com/eZjhmhgd2t -
#JLABSSD Sanjay Mistry highlights@JLABS incubation model is no strings attached, offering mentorship, expertise, & a “community of companies” of shared learning among residents.#BiotechShowcase#JPM20pic.twitter.com/iGjXOWLVeH
-
50% chance of showers, 100% chance of funds -
#JLABSSD resident Locana announces a $55M series A round for their RNA targeting#genetherapyhttp://jlabs.buzz/ltt -
Got a speech coming up soon? Get an insider tip from @johnbates in link below
https://executivespeakingsuccess.com/openings-closings …
Don't forget to be there in person for #jlabssd program 10.17 Register: https://jlabs.buzz/n0v pic.twitter.com/VIM7tZAu9M
-
Show me your holiday cheer!
@chelsbells4@BritSab09#jlabssd pic.twitter.com/2JboUHmRAn -
DYK almost 2x as many women die of lung cancer than breast cancer? *
#JLABSSD gathers leading researchers & innovators to talk breakthrough innovations 11/14 https://jlabs.tv/2JND051 *source: https://jlabs.tv/2PFtQLL pic.twitter.com/07CCDG55bP
-
Congratulations
#JLABSSD resident, Phoenix Molecular Designs who received clearance to enter Phase 1/1b clinical trials for PMD-026 an RSK inhibitor targeting advanced#breastcancer,read more:http://jlabs.buzz/3lq -
Should you hire a grant writer?
Opinions are mixed - a good strategy is to write the grant yourself (nobody knows the science better!) and have an external advisor do a mock review #JLABSSD pic.twitter.com/LSWJzIgAVj
-
Booth is bumping
#HLTH2019 stop by and say hi
donate a photo to a cause! #jlabssd@JLABS@JNJInnovationpic.twitter.com/7Du3hjO716
-
#JLABSSD alumni, Oncternal Therapeutics announces merger w/publicly traded co, GTx. The combined company will develop potential 1st in class therapeutics for cancers https://jlabs.tv/2TEaYz2 -
Fall funding news for Avidity Biosciences - $100M raised to advance pioneering science to treat rare muscle disorders Troy Wilson is a terrific founder and now Sarah Boyce as CEO.
#JLABSSD#JLABSAlumnihttps://jlabs.tv/2qMK9fs -
Shout out to
#JLABSSD alumni Poseida who raised $142M on Series C round of funding. Congratulations!!#CART#GetMoney#Sandiego Read more:http://bit.ly/2GvutS1 -
Is your startup advancing science that could prevent biological, chemical or infectious disease threats? Apply to meet with
@BARDA by 9/5: http://bit.ly/33YcM8x#JLABSSD pic.twitter.com/RVuAtTby1c
-
Shining the
on #JLABSSD alumni@MiratiTx, who's experimental drug may have the potential to significantly reduce tumor size for patients with advanced lung & colorectal cancer. In a small, early-stage trial, 40% of patients saw a reduction in tumor size.https://jlabs.tv/2u2NpoR -
It’s almost time! Tomorrow, come meet the
#JLABSSD team and learn about joining the JLABS @ San Diego community. See you there: https://meetjlabssd.splashthat.com/ pic.twitter.com/pz3Z1uox65
-
#DYK that#JLABSSD was the very first JLABS location? Come check out the facility & meet our team including@JanelleLHunt on 1/29! https://jlabs.tv/2RUM3o9 pic.twitter.com/VwZMBcwoel
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.